GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cutia Therapeutics (HKSE:02487) » Definitions » ROIC %

Cutia Therapeutics (HKSE:02487) ROIC % : -110.19% (As of Jun. 2023)


View and export this data going back to 2023. Start your Free Trial

What is Cutia Therapeutics ROIC %?

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. Cutia Therapeutics's annualized return on invested capital (ROIC %) for the quarter that ended in Jun. 2023 was -110.19%.

As of today (2024-06-05), Cutia Therapeutics's WACC % is 10.03%. Cutia Therapeutics's ROIC % is -129.79% (calculated using TTM income statement data). Cutia Therapeutics earns returns that do not match up to its cost of capital. It will destroy value as it grows.


Cutia Therapeutics ROIC % Historical Data

The historical data trend for Cutia Therapeutics's ROIC % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Cutia Therapeutics ROIC % Chart

Cutia Therapeutics Annual Data
Trend Dec21 Dec22 Dec23
ROIC %
-163.09 -133.54 -130.32

Cutia Therapeutics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23
ROIC % - -229.84 -103.22 -110.19 -146.10

Competitive Comparison of Cutia Therapeutics's ROIC %

For the Biotechnology subindustry, Cutia Therapeutics's ROIC %, along with its competitors' market caps and ROIC % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Cutia Therapeutics's ROIC % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cutia Therapeutics's ROIC % distribution charts can be found below:

* The bar in red indicates where Cutia Therapeutics's ROIC % falls into.



Cutia Therapeutics ROIC % Calculation

Cutia Therapeutics's annualized Return on Invested Capital (ROIC %) for the fiscal year that ended in Dec. 2022 is calculated as:

ROIC % (A: Dec. 2022 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (A: Dec. 2021 ) + Invested Capital (A: Dec. 2022 ))/ count )
=-338.311 * ( 1 - 0% )/( (132.738 + 373.925)/ 2 )
=-338.311/253.3315
=-133.54 %

where

Invested Capital(A: Dec. 2021 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1830.433 - 10.048 - ( 1687.647 - max(0, 23.571 - 1716.367+1687.647))
=132.738

Invested Capital(A: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1615.668 - 49.066 - ( 1202.151 - max(0, 86.436 - 1279.113+1202.151))
=373.925

Cutia Therapeutics's annualized Return on Invested Capital (ROIC %) for the quarter that ended in Jun. 2023 is calculated as:

ROIC % (Q: Jun. 2023 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2022 ) + Invested Capital (Q: Jun. 2023 ))/ count )
=-452.804 * ( 1 - 0% )/( (373.925 + 447.943)/ 2 )
=-452.804/410.934
=-110.19 %

where

Invested Capital(Q: Dec. 2022 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1615.668 - 49.066 - ( 1202.151 - max(0, 86.436 - 1279.113+1202.151))
=373.925

Invested Capital(Q: Jun. 2023 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1956.596 - 33.484 - ( 1530.145 - max(0, 143.666 - 1618.835+1530.145))
=447.943

Note: The Operating Income data used here is two times the semi-annual (Jun. 2023) data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Cutia Therapeutics  (HKSE:02487) ROIC % Explanation

ROIC % measures how well a company generates cash flow relative to the capital it has invested in its business. It is also called ROC %. The reason book values of debt and equity are used is because the book values are the capital the company received when issuing the debt or receiving the equity investments.

There are four key components to this definition. The first is the use of operating income or EBIT rather than net income in the numerator. The second is the tax adjustment to this operating income or EBIT, computed as a hypothetical tax based on an effective or marginal tax rate. The third is the use of book values for invested capital, rather than market values. The final is the timing difference; the capital invested is from the end of the prior year whereas the operating income or EBIT is the current year's number.

Why is ROIC % important?

Because it costs money to raise capital. A firm that generates higher returns on investment than it costs the company to raise the capital needed for that investment is earning excess returns. A firm that expects to continue generating positive excess returns on new investments in the future will see its value increase as growth increases, whereas a firm that earns returns that do not match up to its cost of capital will destroy value as it grows.

As of today, Cutia Therapeutics's WACC % is 10.03%. Cutia Therapeutics's ROIC % is -129.79% (calculated using TTM income statement data).


Be Aware

Like ROE % and ROA %, ROIC % is calculated with only 12 months of data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.


Cutia Therapeutics ROIC % Related Terms

Thank you for viewing the detailed overview of Cutia Therapeutics's ROIC % provided by GuruFocus.com. Please click on the following links to see related term pages.


Cutia Therapeutics (HKSE:02487) Business Description

Traded in Other Exchanges
N/A
Address
436 Heng Feng Road, 20th Floor, Huanzhi Building, Jingan District, Shanghai, CHN, 200070
Cutia Therapeutics is a dermatology-focused biopharmaceutical company focused on the broader dermatology treatment and care therapeutic areas, including localized adipose accumulation management medication, scalp diseases and care, skin diseases and care, and topical anesthesia. Its core product is CU-20401, which is a recombinant mutant collagenase that targets obesity, overweight, or other localized adipose accumulation-associated metabolic diseases.
Executives
Pandanus Associates Inc. 2201 Interest of corporation controlled by you
Pandanus Partners L.p. 2201 Interest of corporation controlled by you
Fil Limited 2201 Interest of corporation controlled by you
Shen Nan Peng 2201 Interest of corporation controlled by you
Snp China Enterprises Limited 2201 Interest of corporation controlled by you
Hongshan Capital Growth Fund V, L.p. 2201 Interest of corporation controlled by you
Hsg Growth V Holdco Q, Ltd 2201 Interest of corporation controlled by you
Hsg Growth V Management, L.p. 2201 Interest of corporation controlled by you
Hsg Holding Limited 2201 Interest of corporation controlled by you
Ma Yun 2201 Interest of corporation controlled by you
Su Zhou Tong Yu Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Su Zhou Yun Zhang Tou Zi Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Su Zhou Tong He Er Qi Chuang Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Su Zhou Fu Yan Chuang Ye Tou Zi Guan Li He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Aurora Cutis Limited 2301 Trustee

Cutia Therapeutics (HKSE:02487) Headlines

No Headlines